Quantum-Si to Highlight Significant Proteus™ Platform Development Progress and Provide Insights into the Company's Industry Leading Technology Pipeline at Investor & Analyst Day

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the key items to be presented at its Investor & Analyst Day that is being hosted in New York City.

Among other advances, the management team will provide updates on:

• Proteus™ platform development including recent development data
• A long-term technology roadmap that addresses the path to billions of reads
• The path to coverage of all 20 amino acids
• A suite of post-translational modification (PTM) methods enabled by the Company's core technology
• The path to Proteus commercial launch including timeline and key technical and commercial milestones

"We are very excited to share a comprehensive update across all of our development efforts and provide insights into our pipeline of new capabilities, that we believe, demonstrates that we have the most comprehensive, compelling and actionable technology roadmap in proteomics," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "First, we have successfully completed sequencing on a prototype Proteus unit, which not only was a key milestone we wanted to achieve before year end 2025, but it occurred faster than originally anticipated, once again highlighting our proven ability to deliver our development programs on time as we have over the past three years. Further, we have not simply completed one sequencing run on our prototype system but have performed over 50 sequencing runs across multiple Proteus prototype systems. As we will highlight at our live event, I am very pleased to report the data from these prototype runs are already meeting or exceeding the performance of our current Platinum^® Pro system, and with the additional development and optimization efforts planned, we believe Proteus will far exceed our current platform technology across every measure of performance."

Hawkins continued, "In addition to our significant platform development progress, through various collaborations, applications of state-of-the-art computational tools, and our rich set of proprietary training data, we have unlocked an accelerated path to detecting all 20 amino acids in the very near term. And finally, we will present data regarding multiple methods in development to enable very high proteome-wide PTM coverage in combination with the significant sequencing output and performance gains of Proteus."

Investor Day Attendance

The Company's Investor and Analyst Day will occur today, November 19th beginning at 10:00 a.m. Eastern Time. Interested parties can attend the meeting virtually by registering here.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway, anticipated data and product launches (including Proteus), investor confidence in Quantum-Si and our strategic roadmap, and any financial guidance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company's ongoing leadership transitions and succession planning; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum protein sequencing instruments and kits and the Company's other products (including Proteus) once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; the Company's defense and initiation of litigation matters; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251119647819/en/

Investor and Media

Jeff Keyes

Chief Financial Officer

[email protected]